A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[2]Chinese Academy of Medical Sciencesand Peking Union Medical College Hospital Beijing, Beijing, China, 100032[3]Beijing Shijitan Hospital Affiliated to Capital Medical University Beijing, Beijing, China, 100038[4]Beijing Tsinghua Changgung Hospital Beijing, Beijing, China, 102218[5]Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, Beijing, China[6]Chongqing Cancer Hospital Chongqing, Chongqing, China, 400000[7]The First Affilited Hospital of Chongqing Medical University Chongqing, Chongqing, China, 400042[8]Guangdong Provincial People's Hospital Guangzhou, Guangdong, China, 510030[9]Guangxi Medical University Affiliated Tumor Hospital Nanning, Guangxi Zhuang Autonomous Region, China, 530021[10]The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, China, 530021[11]The fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050010河北医科大学第四医院[12]Affiliated Tumor Hospital of Harbin Medical University Harbin, Heilongjiang, China, 150000[13]AnYang Tumor Hospital Anyang, Henan, China, 455000[14]Zhongnan Hospital of Wuhan University Wuhan, Hubei, China, 430061[15]Hunan Cancer Hospital Changsha, Hunan, China, 410013[16]Nantong Tumor Hospital Nantong, Jiangsu, China, 226000[17]The First Hospital of Jilin University Changchun, Jilin, China, 130021[18]Yanbian University Hospital Yanji, Jilin, China, 133000[19]The First Hospital of China Medical University Shenyang, Liaoning, China, 110011[20]Liaoning Cancer Hospital & Institute Shenyang, Liaoning, China, 110042[21]Qilu Hospital of Shandong University Jinan, Shandong, China, 250000[22]Shanxi Cancer Hospital Taiyuan, Shanxi, China, 030013[23]The Second Affiliated Hospital of PLA Airforce Military Medical University Xi'an, Shanxi, China, 710032[24]The First Affiliated Hospital of Xi'an Jiaotong University Xi'an, Shanxi, China, 710061[25]Shanxi Provincial People's Hospital Xi'an, Shanxi, China, 710068[26]The Second People's Hospital of Neijiang Neijiang, Sichuan, China, 641100[27]Tianjin Cancer Hospital Tianjin, Tianjin, China, 300060[28]Xinjiang Uiger Municipal People's Hospital Urumqi, Xinjiang, China, 830000[29]Zhejiang Cancer Hospital Hangzhou, Zhejiang, China, 310022[30]The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang, China, 310052[31]The Fourth Affiliated Hospital of Anhui Medical University Hefei, Anhui, China, 230022
研究目的：
This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus paclitaxel for injection (albumin bound) in subjects with advanced triple negative breast cancer.
